History
2010’s
2019
- Safety study of 6’-Sialyllactose sodium salt in human
- Changed GeneChem’s Corporate Identity (CI)
- Filing of US FDA GRAS notice for 6’-Sialyllactose sodium salt
2018
- Received US FDA GRAS status for 3’-Sialyllactose sodium salt (GRN766)
2017
- Completion of Self-affirmed GRAS evaluation for 3’-Sialyllactose sodium salt and 6’-Sialyllactose sodium salt in the USA
- Registration for Cosmetics Manufacturing and Sales Business
- Acquired the GLP toxicology study data for 6’-Sialyllactose sodium salt
- Acquired Intellectual Property (IP) management Certification
- Acquired ISO 9001:2015 Certification
2015
- Acquired INNOBIZ Company Certification
2014
- Signed contract for domestic exclusive supply rights with LG Household & Healthcare Co. Ltd. for AquaGG®
2013
2010
- Acquired the GLP toxicology study data for 3’-Sialyllactose sodium salt
- Safety study of 3’-Sialyllactose sodium salt in human
2000’s
2009
- Completed development of pilot scale production process for 3’- & 6’-Sialyllactose
2007
- Launched 3’-Sialyllactose for laboratory research
2005
- α-gal Epitopes for xenotransplantation succeeded for the first time in Korea
2004
- Successful development and launch of Cy-fluorescent dye for diagnostic DNA microarray chip
2000
- Technology transfer of location specific gene targeting technology (SGTA™)
- Central Research Laboratory established
1990’s
1997
- GeneChem Inc. established